Press Releases

SALT LAKE CITY, April 16, 2021 / PRNewswire / -- Recursion Pharmaceuticals, Inc. ("Recursion" or "we") today announced the pricing of its initial public offering of its Class A common stock at a price to the public of $18.00 per share. Recursion is offering 24,242,424 shares of its Class A common

Former Goldman Sachs executive to serve as Chairman of Recursion's Board, effective immediately SALT LAKE CITY, March 1, 2021 / PRNewswire / --  Recursion , a digital biology company industrializing drug discovery, today announced the appointment of R. Martin Chavez as Chairman of its Board of

Former VP & Assistant General Counsel at Pfizer to join Recursion's executive team SALT LAKE CITY, Feb. 18, 2021 / PRNewswire / --  Recursion , a biotechnology company scaling more like a technology company, today announced the appointment of Louisa Daniels, J.D., MBA as its Chief Legal Officer and

Former Chief Medical Officer of Blade Therapeutics and Genentech Group Medical Director to lead Recursion’s clinical development programs SALT LAKE CITY--( BUSINESS WIRE )-- Recursion , a digital biology company industrializing drug discovery, today announced the appointment of Dr.

- Drug discovery partnership and equity investment led by Leaps by Bayer in Series D financing round - Digitally-powered drug discovery to address fibrotic diseases with previously undiscovered mechanisms and to deliver novel therapies to patients faster Berlin, Germany and Salt Lake City, USA,

− Proceeds to support Recursion’s development of its broad clinical-stage pipeline and expansion of the capabilities of its drug discovery platform − − Series D financing led by Leaps by Bayer and supported by a consortium of new and existing healthcare and technology investors − SALT LAKE CITY,

SALT LAKE CITY--( BUSINESS WIRE )--Recursion, a digital biology™ company leading in the industrialization of drug discovery, today announced its acquisition of Vium, a digital vivarium™ company. Vium’s platform combines computer vision, machine learning and sensor technologies to non-invasively

More than 305,000 high-resolution, multi-channel COVID-19 cellular images captured in less than four weeks with Molecular Devices ImageXpress® Micro Confocal High-Content Imaging System are now available to the scientific community. SAN JOSE, Calif. – June 25, 2020 — With the COVID-19 pandemic

SALT LAKE CITY, Nov. 8, 2018 / PRNewswire / --  Recursion Pharmaceuticals , a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover and develop drugs at scale, today announced a $1.6 million Phase 2 Small Business Innovation Research

Award coincides with the opening of Recursion's expansive new R&D facility SALT LAKE CITY, Nov. 5, 2018 / PRNewswire / --  Recursion Pharmaceuticals , a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover and develop drugs at scale, has